REGENXBIO Inc. 8-K

What Happened

• REGENXBIO Inc. (RGNX) filed an 8-K reporting results from its May 29, 2026 Annual Meeting and announcing it commenced a stock option exchange for non-executive employees on June 3, 2026. About 42,818,883 shares were represented (~82.95% of shares entitled to vote).
• Directors elected for Class II terms through 2029: Jean Bennett, M.D., Ph.D.; A.N. “Jerry” Karabelas, Ph.D.; and Daniel Tassé. The company also ratified PricewaterhouseCoopers LLP as auditor and won an advisory “say-on-pay” vote.

Key Details

• Shareholder turnout: 42,818,883 shares represented (≈82.95%).
• Director election votes:
  • Jean Bennett: 24,025,836 for; 11,238,926 withheld; 7,554,121 broker non-votes.
  • A.N. “Jerry” Karabelas: 27,124,923 for; 8,139,839 withheld; 7,554,121 broker non-votes.
  • Daniel Tassé: 32,039,753 for; 3,225,009 withheld; 7,554,121 broker non-votes.
• Auditor ratification: PwC ratified (42,526,553 for; 244,785 against; 47,545 abstain).
• Advisory executive compensation (“say-on-pay”): approved (32,392,302 for; 2,722,825 against; 149,635 abstain; 7,554,121 broker non-votes).
• Stock option exchange votes:
  • Approved for non-executive employees (26,352,456 for; 8,853,230 against; 59,076 abstain).
  • Not approved for executive employees (14,097,815 for; 21,021,531 against; 145,416 abstain).
• Exchange offer details: commenced June 3, 2026 and runs through July 1, 2026 (unless extended). Eligible options: outstanding options under the 2015 Equity Incentive Plan with exercise price ≥ $18.00; exchanged for fewer options with an exercise price equal to the fair market value on the new grant date (expected first business day after offer ends). Company does not expect a significant change to stock compensation expense. A Tender Offer Statement is expected to be filed with the SEC.

Why It Matters

• Governance: The election results and auditor ratification confirm the board and independent auditor that will guide strategy and financial oversight through 2029 and 2026, respectively. The advisory approval of executive pay indicates shareholder support for disclosed compensation practices.
• Capital structure and employee incentives: Approval and launch of the non-executive option exchange could reduce the number of outstanding underwater or high-strike options and reset exercise prices, which may affect future dilution and incentive alignment; the company says material stock compensation expense is not expected to change significantly. The executive exchange was rejected, so executive option terms remain unchanged.
• Near-term investor actions: Watch the Tender Offer Statement and the exchange offer results (after July 1, 2026) for details on participation levels and any reported impact on outstanding option counts and dilution.